Insider Selling: CeriBell (NASDAQ:CBLL) CEO Sells $521,775.38 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 20,846 shares of CeriBell stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $25.03, for a total value of $521,775.38. Following the completion of the transaction, the chief executive officer owned 746,345 shares of the company’s stock, valued at $18,681,015.35. The trade was a 2.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Xingjuan Chao also recently made the following trade(s):

• On Wednesday, September 2nd, Xingjuan Chao sold 39,540 shares of CeriBell stock. The stock was sold at an average price of $24.61, for a total transaction of $973,079.40.
• On Friday, August 21st, Xingjuan Chao sold 6,068 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total transaction of $145,753.36.
• On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total transaction of $786,317.45.
• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total transaction of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $19.90, for a total transaction of $776,100.00.

CeriBell Stock Up 2.0%

Shares of CBLL traded up $0.50 during midday trading on Thursday, reaching $25.00. The stock had a trading volume of 734,947 shares, compared to its average volume of 280,012. The company has a market cap of $959.50 million, a price-to-earnings ratio of -14.20 and a beta of 0.95. The company’s fifty day simple moving average is $21.51 and its two-hundred day simple moving average is $19.79. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $25.63. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The business had revenue of $28.10 million for the quarter, compared to analysts’ expectations of $27.28 million. Equities research analysts expect that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CBLL. BlackRock Inc. acquired a new stake in shares of CeriBell during the second quarter worth about $37,657,000. KCM Capital Inc raised its stake in CeriBell by 40.0% during the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after acquiring an additional 400,000 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in CeriBell during the 2nd quarter worth approximately $17,437,000. TimesSquare Capital Management LLC purchased a new position in shares of CeriBell in the 2nd quarter valued at approximately $15,182,000. Finally, Royce & Associates LP purchased a new stake in shares of CeriBell during the fourth quarter worth approximately $11,695,000.

Analysts Set New Price Targets

CBLL has been the topic of a number of research analyst reports. Barclays raised shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Canaccord Genuity Group lifted their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Raymond James Financial restated a “strong-buy” rating and issued a $29.00 price objective on shares of CeriBell in a research note on Thursday, September 3rd. BTIG Research reiterated a “buy” rating and set a $30.00 target price on shares of CeriBell in a research report on Friday, September 11th. Finally, Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and a consensus target price of $24.40.

About CeriBell

Ceribell, Inc (NASDAQ: CBLL) is a medical technology company focused on improving the detection and management of seizures and other neurological conditions in hospital settings. Its products are designed to make electroencephalography (EEG) more accessible at the point of care, particularly in emergency departments, intensive care units and other settings where conventional EEG testing may be delayed or difficult to obtain.

The company’s primary offering is the Ceribell Rapid Response EEG system, which combines a portable EEG recorder, a simplified electrode headband and software for acquiring and reviewing brain-wave data.